Last Price
1.30
Today's Change
-0.05 (3.70%)
Day's Change
1.29 - 1.36
Trading Volume
58,814
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Jeffrey Frelick Mr. Jeffrey Frelick
Full Time Employees: 2 2
IPO Date: 2021-10-13 2021-10-13
CIK: 0001419554 0001419554
ISIN: US0980705018 US0980705018
CUSIP: 098070303 098070303
Beta: 0.70 0.70
Last Dividend: 0.00 0.00
Dcf Diff: -15.83 -15.83
Dcf: 19.80 19.80
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.